Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

New York and Vancouver, BC –  May 28, 2025 – Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Ian McDonald, Chief Executive Officer, and…

Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025

– Key Opinion Leaders (KOLs) on Absence seizures include Dennis Dlugos, MD, Wendyl D’Souza, MBChB, MPH, FRACP, PhD, and Alexander Rotenberg, MD, PhD –   Vancouver, British Columbia, May 20, 2025 – Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a company focused on developing highly selective 5-HT2 agonists for…

Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101

BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model – The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) – Findings highlight BMB-101’s potential to address critical gaps in SUDEP prevention –   New York and Vancouver, British Columbia, May 13, 2025 – Bright Minds Biosciences Inc.…

Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

Vancouver, British Columbia, April 28, 2025 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that it will host a virtual R&D Day on Tuesday, May…

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research

— Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O’Brien, MD; Jo Sourbron, MD, PhD, MPharm; and Joseph Sullivan, MD, bring decades of experience in epilepsy drug developmentand research to support Company’s clinical focus on epilepsy —   Vancouver, British Columbia, March 4,2025 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ: DRUG) (“Bright Minds” or the…

Bright Minds Biosciences to Participate at Three Healthcare Conferences in March

New York and Vancouver, BC – February 24, 2025 – Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Ian McDonald, Chief Executive Officer, and…

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

— Dr. Collins brings extensive drug development and clinical expertise in epilepsy —   New York and Vancouver, BC – January 07, 2025 – Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other…